Neurofeedback Training's Efficiency for Attentionnal Performances

NCT ID: NCT05924659

Last Updated: 2024-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-25

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomised, double bling and controled study aim to evaluate the performance of a neurofeedback training on attentional capabilities, in comparison to placebo. We hypothesize 1) that an electroencephalographic (EEG) based neurofeedback training may improve attentional performances of healthy subjects, and 2) inter-individual variability might be explained by factors such as body awarness, sleep parameters and genetics of individuals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many jobs require high attentional performances that are maintained over time, which imply safety issues. Just like physicial performances of top athletes, it is possible to use a set of innovative methods and technologies to improve cognitive performances (attention, working memory, decision making… ), in particular with the help of brain training programs such as neurofeedback protocoles. Although neurofeedback training efficiency has been evaluated in many context (either with patients or healthy subjects), it is still a subject of debate. More specifically, inter-individual variability is far from beeing understood. We hypothesize 1) that an electroencephalographic (EEG) based neurofeedback training may improve attentional performances of healthy subjects, and 2) inter-individual variability might be explained by factors such as body awarness, sleep parameters and genetics of individuals.

1. To demonstrate the efficiency of EEG neurofeedback (EEG-NFB) trainings versus a control group, we will compare the conflict monitoring score obtained with the Attentional Network Task (Reaction Times (RT) in ms of Incongruent trials minus Reaction Times of Congruent trials : RTincongruent - Rtcongruent). Our hypothesis is a reduction of the conflict monitoring scores after the EEG-NFB compared to baseline (before EEG-NFB), and a lower score for the EEG-NFB group compared to the control group.
2. To describe the different factors influencing EEG-NFB training efficacy, we will explore the inter-individual variability by assessing the body awarness (especially cardiac interoceptive accuracy with a counting task), sleep parameters (hypnogram, sleep power spectral activities) and genetic polymorphisms (DRD2, COMT, DAT1, PER3, ADA, ADORA2A, TNF-α).

The study design will be a controlled interventional protocol, double-blinded with parralel-arms (EEG-NFB vs Control) in healthy volunteers.

* Prior informations will be given to individuals expressing an interest in this study.
* During the inclusion, an investigator or a member of the research team will verbally reiterate the informations and answer any additional questions. The volunteer will be reminded of his/her rights in the contexte of research involving the human person.
* After verifying volunteer's eligibility criteria, he/she will be asked to sign the consent form.
* Volunteers will have to fill out a sleep questionnaire.Sleep/wake cycles will be home monitored with a wearable headset during 14 days : 7 days before the start of EEG-NFB training, and 7 during the EEG-NFB training.
* Cognitive tests will be done each day of EEG-NFB training (or control) : Psychomotor Vigilance Task, Attentional Network Test, AX-Continuous Performance Test and a Heartbit Counting task. The cognitive test period will last 30 minutes.
* EEG-NFB training (or control) will be done for 5 consecutive days, each session lasts 35 min (10 blocs of 3 min, and short breaks of 30 s). Each session will be precedeed and followed by a resting-state recording. The control group will perform a SHAM EEG-NFB.
* Before the first session and after the last (5th) session, cortisol and α-amylase concentrations will be evaluated by saliva tests.
* Before the session and after the last session, questionnaires evaluating body awarness will be filled out by volunteers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention-deficit

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized assigment, neurofeedback training versus control
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
Double bling computizded neurofeed back training

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neurofeedback Training

1 week of cerebral training with a neurofeedback strategy based on increased alpha EEG activity

Group Type EXPERIMENTAL

Cerabral training

Intervention Type OTHER

1 week of cerebral training (neurofeedback or sham)

Control

1 week of cerebral training with a strategy based on time on task increase of performance, without neurofeedback

Group Type SHAM_COMPARATOR

Cerabral training

Intervention Type OTHER

1 week of cerebral training (neurofeedback or sham)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cerabral training

1 week of cerebral training (neurofeedback or sham)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy male or female volunteers
* aged between 18 yo and 50 yo.

Exclusion Criteria

* any pathological issues,
* previous traumatic brain and/or auditive injuries,
* volunteers having already experienced NFB trainings,
* high tobacco consumers,
* volunteers refusing genotyping.
Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hotel Dieu de France Hospital

OTHER

Sponsor Role collaborator

University of Paris 5 - Rene Descartes

OTHER

Sponsor Role collaborator

Institut de Recherche Biomedicale des Armees

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut de recherche biomédicale des armées

Brétigny-sur-Orge, , France

Site Status RECRUITING

Hotel Dieu

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fabien SAUVET, MD

Role: CONTACT

+33662209331

Fabien SAUVET, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fabien SAUVET

Role: primary

0033 6 62 20 93 31

Damien Leger, Pr

Role: primary

00330112654543

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A02306-37

Identifier Type: OTHER

Identifier Source: secondary_id

2023_ENOCA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neurofeedback in Clinical High Risk
NCT06492343 NOT_YET_RECRUITING NA